Chargement en cours...
ARETTA: Assessing Response to Neoadjuvant Taxotere and Subcutaneous Trastuzumab in Nigerian Women With HER2-Positive Breast Cancer: A Study Protocol
Human epidermal growth factor receptor 2 (HER2) subtype of breast cancer is aggressive, leading to a poor outcome. Targeted therapy with trastuzumab has been shown to be effective in the treatment of HER2-positive breast cancer. Cardiotoxicity is a specific adverse effect associated with trastuzumab...
Enregistré dans:
| Publié dans: | JCO Glob Oncol |
|---|---|
| Auteurs principaux: | , , , , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
American Society of Clinical Oncology
2020
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7392776/ https://ncbi.nlm.nih.gov/pubmed/32628583 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/GO.20.00043 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|